Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Goodbody Health Ltd on Friday reported a significant drop in an annual revenue, as focus moves away from Covid-19 products.
Goodbody is a Somerset, England-based aggregator of health and wellness services and products. With over 52 products, tests include blood, genetic, Covid and other diagnostic solutions, with more than 200,000 tests completed to date.
The company said that revenue in 2022 fell by 42% to £10.0 million from £17.1 million a year earlier. Pretax loss widened to £4.5 million from £2.2 million.
Goodbody said that the fall in profit and revenue is ‘not surprising’, as the majority of the turnover in 2021 was generate by Covid-19 testing income.
Looking ahead, Goodbody said that it is ‘well positioned’ as part of the private healthcare revolution in diagnostic wellness testing and services to support preventative health interventions and lifestyle changes
Chief Executive Officer George Thomas said:‘The company, having successfully switched to being a recognised diagnostic wellness testing provider, now provides services throughout the sector. The results for 2022, while lower than the previous year, support the switch that has been made and show the true potential of the company we have built, and a clear strategy in the Health & Wellness Sector.’
Shares in Goodbody Health were untraded at 0.90 pence each in London on Friday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.